| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 10, 2020Fashion Show Highlights the #ThisIsMBC Beneath the Breast Campaign
Presenting sponsor Eisai Inc. and METAvivor announce today that they have joined forces with AnaOno Intimates and #Cancerland to fearlessly unite the breast cancer community and shine a spotlight...
-
Feb 3, 2020Executive Appointments:
As Eisai Inc. continues to bring innovative medicines and dynamic solutions to the marketplace, the company announces today the expansion of its leadership team to include two key appointments in...
-
Jan 22, 2020
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it has been selected as the highest rated company “A” in the Climate Change Report 2019 issued by the...
-
Jan 21, 2020Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Eisai announced today the presentation of three abstracts at the 2020 Gastrointestinal Cancers Symposium (#GI20) in San Francisco from January 23-25. New data to be presented on lenvatinib...
-
Dec 27, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that JAMA Network Open (www.jamanetwork.com) published results of SUNRISE 1 (Study 304), a pivotal Phase 3...
